An interleukin is a member of a historically named group of cytokines: signaling proteins that regulate communication between cells. Interleukins influence the development, survival, movement, and activity of immune cells, while also acting on epithelial cells, blood vessels, connective tissues, and other organs. Their name originally referred to communication between leukocytes, but neither their production nor their effects are restricted to white blood cells.
Interleukins are central to the organization of the immune system. They connect the rapid responses of innate immunity with the antigen-specific responses of adaptive immunity, coordinate defense against different classes of pathogens, and help restrain damaging inflammation. They also participate in blood-cell formation, tissue repair, and maintenance of physiological barriers. Abnormal interleukin production or signaling contributes to inherited immune disorders, chronic inflammatory diseases, allergy, and some cancers.
The designation “interleukin” does not identify a single molecular family. Numbered interleukins include proteins with different structures, evolutionary histories, receptors, and signaling mechanisms. Understanding their effects therefore requires attention to the particular interleukin, its receptor, the responding cell, and the surrounding biological context.
Historical development and nomenclature
The interleukin concept emerged from experiments showing that immune cells communicate through soluble factors. During the 1950s and 1960s, investigators found that culture fluids from activated leukocytes could alter the behavior of other cells. Before the responsible molecules were purified, they were commonly named for an observed activity or an apparent cellular source. Terms such as “lymphocyte-activating factor,” “T-cell growth factor,” “lymphokine,” and “monokine” reflected this experimental approach.
In 1976, Doris Morgan, Francis Ruscetti, and Robert Gallo reported sustained growth of human T lymphocytes using a growth-promoting activity in conditioned culture medium. This work helped establish the importance of the factor subsequently called interleukin-2, or IL-2. Long-term T-cell culture became an important experimental platform for studying lymphocyte biology. However, an activity measured in a culture fluid did not necessarily represent one molecule: several cytokines could produce overlapping effects, and one cytokine could affect multiple cell types.
The term interleukin was proposed in 1979 to provide a common nomenclature for soluble mediators involved in leukocyte communication. IL-1 encompassed activities associated with lymphocyte activation, whereas IL-2 designated the T-cell growth-promoting activity. Protein purification, complementary DNA cloning, and recombinant DNA technology subsequently allowed investigators to distinguish individual molecules and test their activities with defined reagents. Molecular cloning also exposed cases in which factors discovered independently under different names were the same protein.
The numbering system largely records the history of designation rather than a biological hierarchy. Adjacent numbers do not imply related structures or functions. Conversely, related molecules may have names that obscure their relationship: IL-4 and IL-13 share important receptor components and biological effects, while IL-12 and IL-23 share a protein subunit. IL-1α and IL-1β are distinct proteins that signal through the same principal signaling receptor.
Not every cytokine is an interleukin. Interferons, tumor necrosis factors, chemokines, and several colony-stimulating factors retain separate names. Nor does an interleukin number guarantee that all proposed activities have been established equally well. Some molecules were initially characterized through limited assays or particular experimental systems. Modern descriptions therefore distinguish accepted molecular identity from proposed functions, especially when findings from cultured cells or animal models have not been demonstrated in humans.
Molecular diversity and family relationships
Interleukins are usually classified more informatively by structural family, receptor usage, or evolutionary relationship than by number. Many are relatively small secreted proteins, frequently with mature polypeptide masses in the approximate range of 10–30 kilodaltons, although glycosylation, precursor processing, and multimeric assembly produce important exceptions. Their biological activity depends on three-dimensional structure, receptor-binding surfaces, and sometimes association with another protein chain.
A large group has a fold built around a bundle of four α-helices. This broad structural category includes cytokines with very different effects, such as IL-2, IL-4, IL-6, and IL-10. Shared architecture does not mean identical receptor usage. IL-2 belongs to a receptor-sharing group associated with the common γ chain, whereas IL-6 uses the signaling component gp130. The IL-10 family includes IL-10 itself and several cytokines that act particularly strongly on epithelial tissues.
The IL-1 family has a different architecture, characterized by a β-trefoil fold. It includes IL-1α, IL-1β, IL-18, IL-33, and the IL-36 cytokines, together with related antagonistic or regulatory molecules. Several members act as signals of infection, cellular stress, or tissue damage. Their activity is often controlled by proteolytic processing or by regulated release, although the details differ substantially between individual family members.
The IL-12 family illustrates how interleukin identity can depend on combinations of subunits. IL-12 consists of p35 and p40 chains, whereas IL-23 contains p19 and the same p40 chain. IL-27 consists of p28 and EBI3. Sharing a subunit creates both biological relationships and opportunities for selective or combined therapeutic blockade. An antibody against p40 can inhibit both IL-12 and IL-23, whereas an antibody against p19 selectively targets IL-23.
The IL-17 family is structurally distinct and includes proteins that commonly function as dimers. IL-17A and IL-17F can form homodimers or an IL-17A–IL-17F heterodimer. IL-25, also called IL-17E, belongs to this family but promotes a different pattern of immunity from IL-17A and IL-17F. This illustrates why a shared family designation should not be treated as a claim of functional equivalence.
Interleukin activity may also depend on post-translational modifications. Glycosylation can influence stability, secretion, or clearance, while disulfide bonds help stabilize many extracellular cytokines. Differences between native and recombinant preparations can consequently affect experimental measurements without changing the underlying identity of the interleukin.
Production, processing, and spatial control
Interleukin production is regulated at several stages: activation of the relevant gene, processing and stability of its messenger RNA, protein synthesis, intracellular trafficking, proteolytic maturation, and release. These controls allow a cell to produce a brief signal rather than maintain continuous stimulation. Different interleukins can be regulated at different stages even when they are produced by the same cell.
Recognition of microbial products by macrophages and dendritic cells, for example, activates transcriptional programs that include inflammatory cytokines. In activated T cells, engagement of the T-cell receptor, together with costimulatory signals, induces factors that promote IL-2 transcription. Calcium-dependent signaling, mitogen-activated protein kinases, and other pathways cooperate in this response. Cytokine production is therefore conditional on combinations of signals rather than being an automatic consequence of one receptor interaction.
Many interleukins enter the conventional secretory pathway through the endoplasmic reticulum and Golgi apparatus. IL-1β is an important exception. It is synthesized as an inactive precursor lacking a conventional secretion signal. In many settings, a first stimulus induces precursor expression, while a second activates an inflammasome, a multiprotein complex that activates caspase-1. Caspase-1 processes pro-IL-1β into its mature form and also promotes processes associated with its release. IL-18 can undergo related processing, although its precursor is constitutively present in several cell types.
Release does not always indicate conventional secretion by an intact cell. IL-1α can function as a damage-associated signal when released from injured cells. IL-33 is normally associated with the nuclei of certain epithelial, endothelial, and stromal cells and can signal after tissue damage. These cytokines are often described as alarmins. Their extracellular activity nevertheless depends on additional controls, including proteolysis and chemical inactivation; tissue injury alone does not determine the final biological response.
Most interleukins act locally through autocrine signaling, in which a cell responds to its own product, or paracrine signaling, in which nearby cells respond. Extracellular binding, receptor-mediated uptake, degradation, and physical tissue organization limit their range. Some can also produce systemic effects. IL-6 released during inflammation acts on the liver to induce acute-phase proteins, linking a local disturbance to a body-wide response.
Spatial presentation can be as important as concentration. IL-15 is frequently presented by IL-15 receptor α on one cell to signaling receptor components on a neighboring cell. This mechanism, called trans-presentation, supports communication between physically adjacent cells and differs from a simple model in which freely soluble cytokine distributes uniformly through a tissue.
Receptors and intracellular signaling
An interleukin changes cell behavior by binding a specific receptor or receptor complex. Receptor expression determines which cells can respond, while the receptor’s intracellular partners determine how binding is translated into altered gene expression, survival, proliferation, or metabolism. The same interleukin can therefore produce different outcomes in different cell types.
Many interleukin receptors signal through the JAK–STAT signaling pathway. Ligand binding brings receptor-associated Janus kinases into an active arrangement. These kinases phosphorylate receptor sites and STAT proteins, which then form complexes and regulate transcription in the nucleus. Different combinations of JAK and STAT proteins help distinguish cytokine responses. IL-2 strongly activates STAT5, IL-4 prominently activates STAT6, and IL-6 commonly activates STAT3, although none of these pathways is restricted to a single molecular route.
Shared receptor components create functional relationships between otherwise distinct cytokines. The common γ chain, encoded by IL2RG, participates in receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The common β chain is shared by receptors for IL-3, IL-5, and granulocyte–macrophage colony-stimulating factor. Several IL-6-family cytokines use gp130. Sharing permits coordinated regulation but does not make the cytokines interchangeable: additional receptor chains, expression patterns, and signaling dynamics preserve specificity.
IL-1-family and IL-17-family receptors use different signaling systems. IL-1 receptors contain intracellular Toll/interleukin-1 receptor domains and commonly recruit the adaptor MyD88, leading to activation of NF-κB and other inflammatory pathways. IL-17 receptors recruit the adaptor ACT1 and can regulate both transcription and the stability of inflammatory messenger RNAs. These mechanisms help explain why blocking one cytokine family cannot be assumed to reproduce the effects of blocking another.
Receptor architecture also influences sensitivity. The high-affinity IL-2 receptor contains IL-2 receptor α, also called CD25, together with IL-2 receptor β and the common γ chain. CD25 captures IL-2 but does not itself provide the principal intracellular signal. Cells expressing the complete complex can respond to lower concentrations than cells possessing only the signaling β and γ chains.
Signals are restrained by receptor internalization, phosphatases, suppressor of cytokine signaling proteins, and inhibitory feedback. Soluble receptors add another layer of control. Soluble IL-6 receptor can form a signaling complex with IL-6 that activates gp130-bearing cells lacking membrane IL-6 receptor, a process called trans-signaling. By contrast, other soluble receptors primarily bind cytokines without transmitting a signal and can act as extracellular inhibitors.
Innate defense and inflammatory coordination
Interleukins organize innate defense by connecting pathogen recognition to changes in vascular function, leukocyte recruitment, antimicrobial activity, and systemic physiology. They do not generally kill pathogens directly. Instead, they regulate the cells and tissues that contain infection, making the timing and location of their production crucial.
IL-1 and IL-6 are prominent early inflammatory mediators. IL-1 promotes activation of vascular endothelium and induces additional cytokines and chemokines, facilitating leukocyte recruitment into affected tissues. IL-6 stimulates hepatocytes to produce acute-phase proteins such as C-reactive protein and fibrinogen. Both contribute to pathways involved in fever. These responses can be protective during infection but can also damage tissue when excessive or prolonged.
IL-12 and IL-18 cooperate in stimulating natural killer cells and certain T-cell populations to produce interferon-γ. Interferon-γ enhances antimicrobial functions of macrophages, an important component of defense against some intracellular pathogens. The effectiveness of this pathway is demonstrated by inherited defects that impair IL-12 or interferon-γ signaling and increase susceptibility to particular mycobacterial and other infections. The pathway is a network, however: neither IL-12 nor IL-18 acts independently of the responding cell’s activation state and surrounding signals.
IL-17A and IL-17F are especially important at epithelial barriers. They stimulate epithelial and stromal cells to produce chemokines and growth factors that recruit and support neutrophils. These responses contribute to defense against extracellular bacteria and fungi. Inherited abnormalities affecting IL-17 immunity can cause chronic mucocutaneous candidiasis, illustrating the importance of this pathway in controlling Candida at skin and mucosal surfaces.
Other interleukins coordinate type 2 innate responses. IL-25 and IL-33 can activate group 2 innate lymphoid cells, which produce IL-5 and IL-13. These signals support eosinophil accumulation, mucus production, and responses associated with helminth infection. They also participate in allergic inflammation. The same circuit can therefore contribute to useful defense in one context and persistent disease in another.
Innate inflammation contains its own restraints. IL-10, produced by several immune-cell populations, suppresses aspects of macrophage and dendritic-cell activation, including production of inflammatory mediators. IL-1 receptor antagonist competes with IL-1 for receptor binding without initiating the corresponding signal. Such mechanisms limit collateral tissue damage, but their effects depend on timing: suppression that protects tissue can also reduce antimicrobial activity under some circumstances.
Lymphocyte development and adaptive immune responses
Interleukins influence adaptive immunity from the development of lymphocytes to the maintenance of long-lived responses. They operate alongside antigen recognition, costimulation, and cell–cell interactions rather than replacing these processes. A cytokine can promote proliferation in one setting, differentiation in another, and survival or regulation in a third.
IL-7 supports important stages of lymphocyte development and the maintenance of many resting T cells. IL-15 is particularly important for natural killer cells and for the homeostasis of memory CD8 T-cell populations. IL-2 promotes expansion of activated T cells but also has an essential role in maintaining regulatory T cells. These cells express high levels of CD25 and help preserve immune tolerance. Consequently, loss of IL-2 signaling can produce immune dysregulation rather than merely a weak immune response.
Differentiation of CD4 helper T cells reflects interactions between cytokines and lineage-associated transcription factors. IL-12 favors type 1 helper responses associated with interferon-γ production. IL-4 favors type 2 helper differentiation and activates STAT6-dependent programs. IL-6, IL-1, transforming growth factor-β, and IL-23 participate in the development or maintenance of IL-17-producing T cells, with important differences between species and experimental conditions. IL-23 is particularly significant for sustaining pathogenic type 17 responses in several inflammatory settings.
These categories are useful but not absolute. Individual T cells can change their cytokine output, and tissue-resident populations may combine features that do not fit a simple lineage diagram. Cytokine effects also depend on the developmental stage of the target cell. An interleukin that promotes early differentiation may have a different effect on an established effector population.
Interleukins also regulate B cells and antibody responses. IL-4 helps direct class-switch recombination toward particular antibody classes, including immunoglobulin E in humans. IL-21, produced prominently by follicular helper T cells, supports B-cell proliferation, differentiation, and germinal-center responses in cooperation with antigen recognition and other signals. These processes contribute to affinity maturation and the production of antibody-secreting plasma cells.
IL-6 supports plasma-cell survival in appropriate tissue environments, while IL-10 can promote some B-cell functions despite its suppressive effects on inflammatory myeloid cells. Such examples illustrate pleiotropy, in which one cytokine has multiple effects. They also demonstrate why “pro-inflammatory” and “anti-inflammatory” are incomplete classifications: an interleukin’s role must be specified in relation to its target cell, tissue, and stage of the response.
Barrier tissues, repair, and physiological maintenance
Interleukin biology extends beyond interactions among circulating immune cells. Epithelial surfaces and their underlying connective tissues both produce and respond to interleukins. These interactions help maintain the intestine, skin, respiratory tract, and other barriers exposed to microbes, mechanical stress, and environmental substances.
IL-22 exemplifies a cytokine whose principal targets are nonhematopoietic cells. It is produced by several lymphocyte populations, whereas its functional receptor is expressed mainly on epithelial and related tissue cells. IL-22 activates programs that can increase antimicrobial protein production, support epithelial survival, and promote regeneration. In the intestine, these effects contribute to separation of the microbiota from underlying tissue. Depending on the disease context and accompanying signals, however, sustained IL-22 activity can also support abnormal epithelial proliferation.
IL-17 and IL-22 often act together at barriers but are not functionally identical. IL-17 strongly promotes recruitment of inflammatory cells through epithelial and stromal mediators. IL-22 acts more directly on epithelial defense and repair programs. Their combined effects can help control infection, while persistent activation can contribute to inflammatory skin disease. The outcome depends partly on whether the initiating disturbance has been removed.
IL-13 influences mucus secretion, smooth-muscle behavior, and connective-tissue remodeling. These activities can contribute to expulsion of helminths, but persistent type 2 signaling is also associated with airway changes in asthma and with fibrotic processes in some tissues. IL-4 and IL-13 can induce alternative activation programs in macrophages, altering their responses to tissue damage and their interactions with fibroblasts and the extracellular matrix. Such macrophage states are heterogeneous rather than a single fixed category.
IL-33 provides another connection between structural tissues and immune cells. Its expression in selected stromal and epithelial populations allows tissue disturbance to activate cells bearing its receptor, ST2. These targets include type 2 innate lymphoid cells, mast cells, and subsets of regulatory T cells. The resulting responses may contribute to repair, allergic inflammation, or other tissue-specific processes.
Interleukins also affect tissues at a distance. IL-6 can be released from contracting skeletal muscle and can influence metabolic physiology, showing that a molecule associated with inflammation also participates in noninfectious signaling. Physiological effects depend on source, duration, concentration, and accompanying mediators. A transient increase during exercise is not equivalent to persistent production during chronic inflammatory disease, even though the same cytokine is involved.
Genetic defects and disease mechanisms
Human genetic disorders provide direct evidence that particular interleukin pathways have indispensable functions. They also reveal that loss of a signaling pathway can cause susceptibility to infection, uncontrolled inflammation, or both. The phenotype depends on the specific molecular defect and the degree to which other pathways can compensate.
Pathogenic variants in IL2RG, encoding the common γ chain, cause a form of X-linked severe combined immunodeficiency. Because this chain participates in several cytokine receptors, the defect disrupts multiple developmental and survival signals. The typical pattern includes profound impairment of T-cell and natural killer-cell development, while B-cell numbers may be preserved despite defective immune function. This is a receptor-sharing disorder, not simply a deficiency of IL-2 responsiveness.
Defects affecting IL-12 receptor β1 can impair responses to both IL-12 and IL-23 and are associated with susceptibility to mycobacterial and certain other infections. In contrast, loss-of-function defects in IL-10 or its receptor can cause severe, very-early-onset intestinal inflammation. These conditions demonstrate the importance of controlling immune responses to the intestinal environment, rather than merely mounting stronger antimicrobial responses.
Excessive IL-1 activity is central to several autoinflammatory disorders. Gain-of-function changes in NLRP3 can cause inappropriate inflammasome activation and increased IL-1β signaling in cryopyrin-associated periodic syndromes. Deficiency of the endogenous IL-1 receptor antagonist, caused by pathogenic variants in IL1RN, produces severe inflammation early in life. These diseases helped establish that dysregulated innate cytokine signaling can drive illness without requiring a conventional antigen-specific autoimmune response.
In more common disorders, interleukins usually function within multifactorial networks. The IL-23–IL-17 axis has a major role in psoriasis. IL-4 and IL-13 contribute to type 2 inflammatory diseases, including atopic dermatitis and subsets of asthma. IL-5 supports eosinophil production and survival. IL-6 contributes to systemic and joint inflammation in rheumatoid arthritis. These associations are supported not only by measurements in affected tissues but also by the effects of pathway-specific treatments.
A raised cytokine concentration alone does not establish causation. It may reflect tissue damage, a compensatory response, or activation of several pathways at once. Likewise, a cytokine can have both protective and pathological functions in the same organ. IL-17 blockade benefits several inflammatory conditions but can worsen inflammatory bowel disease, underscoring the importance of intestinal barrier protection. Disease mechanisms must therefore be established separately for each pathway and clinical setting.
Therapeutic targeting and engineered interleukins
Interleukin-directed medicines use several strategies: supplying a cytokine, blocking the cytokine itself, blocking its receptor, mimicking an endogenous antagonist, or inhibiting downstream signaling. These approaches differ in specificity. A drug against one ligand may affect fewer pathways than a drug against a shared receptor component or intracellular kinase.
Recombinant IL-2, known as aldesleukin, received United States approval for metastatic renal-cell carcinoma in 1992 and metastatic melanoma in 1998. It can stimulate antitumor lymphocyte activity, but high-dose treatment can cause substantial toxicity, including capillary leak syndrome. The contrasting roles of IL-2 in effector T cells and regulatory T cells have motivated engineered variants designed to alter receptor binding, tissue distribution, or persistence. These molecules seek to favor particular cellular responses rather than reproduce all effects of native IL-2.
IL-1-directed agents illustrate different forms of inhibition. Anakinra is a recombinant IL-1 receptor antagonist. Canakinumab is an antibody against IL-1β, while rilonacept is a soluble receptor-based fusion protein that binds IL-1. Their molecular targets are related but not identical. IL-6 signaling can be inhibited by antibodies against the IL-6 receptor, such as tocilizumab, or against IL-6 itself, such as siltuximab.
Shared subunits create opportunities for broader or narrower blockade. Ustekinumab targets the p40 subunit common to IL-12 and IL-23. Agents targeting the IL-23 p19 subunit inhibit IL-23 without directly blocking IL-12. Secukinumab and ixekizumab target IL-17A, whereas brodalumab targets IL-17 receptor A. These distinctions affect which ligands and signaling interactions are interrupted.
Type 2 inflammatory pathways provide further examples. Mepolizumab and reslizumab target IL-5, while benralizumab targets IL-5 receptor α and promotes depletion of eosinophils. Dupilumab targets IL-4 receptor α, inhibiting signaling by both IL-4 and IL-13. Its mechanism reflects the shared receptor biology of these cytokines rather than nonspecific immune suppression.
Clinical benefit and risk must be evaluated for each disease and agent. Interleukin blockade can impair host defense because the targeted pathway also has normal protective functions. Conversely, a pathway strongly implicated in one inflammatory disease may not be useful to block in another. Randomized controlled trials, pharmacological studies, and postmarketing observation establish therapeutic effects; changes in cytokine concentrations alone do not demonstrate clinical efficacy.
Experimental measurement and interpretation
Interleukins can be studied at the levels of gene transcription, protein production, receptor engagement, intracellular signaling, and biological function. These measurements answer different questions. Detection of an interleukin transcript establishes that a gene is being expressed, but it does not prove that active protein has been secreted or that neighboring cells have responded.
Protein concentrations are commonly measured with an enzyme-linked immunosorbent assay or multiplex bead-based assays. Such methods can quantify low concentrations in blood, tissue fluid, or culture supernatants, but results depend on antibody specificity, calibration standards, sample handling, and interference from other molecules. Some assays detect bound and free cytokine differently. Soluble receptors or therapeutic antibodies can alter both biological availability and analytical detection.
Flow cytometry identifies cytokine-producing cells and measures receptor expression or intracellular signaling. Intracellular cytokine staining often uses a stimulation period and secretion inhibitors, so it measures production under specified experimental conditions rather than unmodified activity in the original tissue. Phosphorylation-sensitive assays can reveal STAT activation after cytokine exposure, helping connect receptor expression to functional responsiveness.
Functional bioassays measure outcomes such as cell proliferation, survival, differentiation, or antimicrobial activity. They can establish that a preparation is biologically active, but overlapping cytokine effects complicate interpretation. Neutralizing antibodies, receptor-deficient cells, and genetically modified organisms help identify the responsible pathway. Each approach has limitations: a germline gene deletion can alter development, while an acute blocking experiment may leave previously established cellular programs intact.
RNA sequencing, single-cell methods, and spatial analyses reveal which cells express cytokines and receptors within complex tissues. These approaches have shown that cytokine production is often concentrated in small populations and can vary markedly across neighboring microenvironments. Nevertheless, low transcript abundance, brief expression, and imperfect correspondence between RNA and protein require complementary measurements. Spatial proximity also does not by itself prove communication.
Translation from experimental models to humans requires particular care. Species differ in receptor expression, immune-cell development, and cytokine-dependent differentiation. Laboratory stimulation may use concentrations or combinations unlike those found in tissues. Human genetic studies, tissue analysis, and controlled therapeutic perturbations provide complementary evidence. The most persuasive mechanistic accounts connect a defined cellular source, biologically active interleukin, competent receptor-bearing target, downstream response, and measurable physiological consequence.